Article Figures & Data
Figures
- Fig 1.
Example coronal sections from automatically segmented MR images from a healthy brain (left) and a patient with AD (right). Arrows indicate medial temporal lobe structures. Colors indicate segmented structures as listed in the Table.
Tables
Manual vs automated segmentation
Brain Region ICC Pearson r Cerebral white matter 0.98* 0.98* Cerebral gray matter 0.92* 0.93* Cerebellum 0.96* 0.93† Third ventricle 0.93* 0.92* Fourth ventricle 0.93* 0.90* Lateral ventricle 0.99* 0.99* Inferior lateral ventricle 0.92* 0.89* Hippocampus 0.93* 0.88* Amygdala 0.77* 0.77* Thalamus 0.9* 0.87* Caudate 0.82* 0.75* Putamen 0.89* 0.85* Pallidum 0.76* 0.69* Ventral diencephalon 0.86* 0.80* Nucleus accumbens 0.61† 0.69* Brain stem 0.93* 0.94* Note:—ICC indicates intraclass correlation coefficient.
* P < .001.
† P < .002.
In this issue
Jump to section
Related Articles
Cited By...
- Brain Charts for People Living with Multiple Sclerosis
- Longitudinal Changes in Regional Brain Volumes and Cognition of Professional Fighters With Traumatic Encephalopathy Syndrome
- Longitudinal Brain Atrophy Rates in Presymptomatic Carriers of Genetic Frontotemporal Dementia
- Preliminary Validation of a Structural Magnetic Resonance Imaging Metric for Tracking Dementia-Related Neurodegeneration and Future Decline
- A Large-scale Comparison of Cortical and Subcortical Structural Segmentation Methods in Alzheimers Disease: a Statistical Approach
- Predictive Utility of Marketed Volumetric Software Tools in Subjects at Risk for Alzheimer Disease: Do Regions Outside the Hippocampus Matter?
- Automated brain volumetrics in multiple sclerosis: a step closer to clinical application
- A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
- Mesial Temporal Sclerosis: Accuracy of NeuroQuant versus Neuroradiologist
- An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
- Evaluation of Automatic Measurement of the Intracranial Volume Based on Quantitative MR Imaging
- Predicting MCI outcome with clinically available MRI and CSF biomarkers